/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

HORIZON FLEXIBLE INCOME ETF

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$25.9452 -0.0022(-0.22%) FLXN at 09 Dec 2025 05:43 PM Drug Manufacturers - Specialty & Generic
Lowest Today 25.95
Highest Today 25.95
Today’s Open 25.95
Prev. Close 26.0035
52 Week High 0.00
52 Week Low 0.00
Day’s Range: Low 25.95 High 25.95
52-Week Range: Low 0.00 High 0.00
1 day return -
1 Week return +0.03
1 month return +0.75
3 month return +1.96
6 month return +3.45
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Granahan SC Advantage 0.98

Granahan Inv Mgt Sm-Cap Core Gr 0.12

Rhumbline Advisers 0.10

First Eagle Small Cap Opportunity I 0.09

Northern Small Cap Core I 0.02

CVT Russell 2000 Small Cap Idx I 0.01

Market Status

Strong Buy: 5

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 458.93 M

PB Ratio 35.6151

PE Ratio 0.0

Enterprise Value 574.33 M

Total Assets 251.93 M

Volume 1502

Company Financials

Fund house & investment objective

Company Information Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. As of November 19, 2021, Flexion Therapeutics, Inc. operates as a subsidiary of Pacira BioSciences, Inc..

Organisation Drug Manufacturers - Specialty & Generic

Employees 257

Industry Drug Manufacturers - Specialty & Generic

CEO Dr. Michael D. Clayman M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow